CN107645951B - 用于递送一种或多种生物活性剂的组合物和方法 - Google Patents

用于递送一种或多种生物活性剂的组合物和方法 Download PDF

Info

Publication number
CN107645951B
CN107645951B CN201580074504.0A CN201580074504A CN107645951B CN 107645951 B CN107645951 B CN 107645951B CN 201580074504 A CN201580074504 A CN 201580074504A CN 107645951 B CN107645951 B CN 107645951B
Authority
CN
China
Prior art keywords
present
active agent
weight
amount
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580074504.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107645951A (zh
Inventor
E·希特里特
I·哈拉米
I·阿塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eximore Ltd
Original Assignee
Eximore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eximore Ltd filed Critical Eximore Ltd
Publication of CN107645951A publication Critical patent/CN107645951A/zh
Application granted granted Critical
Publication of CN107645951B publication Critical patent/CN107645951B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201580074504.0A 2014-11-25 2015-11-25 用于递送一种或多种生物活性剂的组合物和方法 Active CN107645951B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084387P 2014-11-25 2014-11-25
US62/084,387 2014-11-25
PCT/IB2015/002345 WO2016083891A1 (en) 2014-11-25 2015-11-25 Compositions and methods for delivering a bio-active agent or bio-active agents

Publications (2)

Publication Number Publication Date
CN107645951A CN107645951A (zh) 2018-01-30
CN107645951B true CN107645951B (zh) 2021-05-04

Family

ID=56073684

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580074504.0A Active CN107645951B (zh) 2014-11-25 2015-11-25 用于递送一种或多种生物活性剂的组合物和方法

Country Status (7)

Country Link
US (3) US10471070B2 (https=)
EP (1) EP3223793B1 (https=)
JP (1) JP6686023B2 (https=)
KR (1) KR102511830B1 (https=)
CN (1) CN107645951B (https=)
CA (1) CA2968926C (https=)
WO (1) WO2016083891A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220444A2 (en) * 2017-05-30 2018-12-06 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
CN111110636B (zh) * 2018-11-01 2022-09-27 复旦大学附属眼耳鼻喉科医院 使用纳米介孔氧化硅高效负载及缓释抗青光眼药物
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
MX2022006803A (es) * 2019-12-04 2022-09-19 Restore Vision Llc Formulaciones oftalmicas para el tratamiento de la presbicia.
WO2022096931A2 (en) * 2020-11-09 2022-05-12 Eximore Ltd. Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof
EP4346720A4 (en) 2021-05-28 2025-01-01 Sight Sciences, Inc. INTRAOCULAR DEVICES, SYSTEMS AND METHODS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505695A (zh) * 2006-06-21 2009-08-12 庄臣及庄臣视力保护公司 用于递送活性试剂的泪点塞
CN101600476A (zh) * 2007-01-31 2009-12-09 爱尔康研究有限公司 泪点塞及输送治疗剂的方法
CN101984745A (zh) * 2007-09-07 2011-03-09 Qlt栓塞输送公司 用于持续释放治疗药物的药物核心
WO2011146483A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
CN103889401A (zh) * 2011-08-29 2014-06-25 Qlt公司 持续释放递送活性剂以治疗青光眼和高眼压

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
DE1300150T1 (de) 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
EP2004172B1 (en) * 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
EP2320972B1 (en) * 2008-05-08 2020-07-01 MiniPumps, LLC Implantable drug-delivery devices
US9095404B2 (en) * 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2303184A4 (en) * 2008-06-24 2013-06-19 Quadra Logic Tech Inc COMBINATION TREATMENT OF GREEN STAR
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US20120238994A1 (en) * 2010-12-22 2012-09-20 Martin Nazzaro Two-piece injectable drug delivery device with heat-cured seal
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
NZ742005A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
JP2016515583A (ja) * 2013-03-27 2016-05-30 フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． オキュラー・インサートおよびその使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101505695A (zh) * 2006-06-21 2009-08-12 庄臣及庄臣视力保护公司 用于递送活性试剂的泪点塞
CN101600476A (zh) * 2007-01-31 2009-12-09 爱尔康研究有限公司 泪点塞及输送治疗剂的方法
CN101984745A (zh) * 2007-09-07 2011-03-09 Qlt栓塞输送公司 用于持续释放治疗药物的药物核心
WO2011146483A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
CN103889401A (zh) * 2011-08-29 2014-06-25 Qlt公司 持续释放递送活性剂以治疗青光眼和高眼压

Also Published As

Publication number Publication date
WO2016083891A1 (en) 2016-06-02
EP3223793A4 (en) 2018-08-01
JP6686023B2 (ja) 2020-04-22
EP3223793A1 (en) 2017-10-04
CA2968926C (en) 2023-01-17
US20210137942A1 (en) 2021-05-13
KR102511830B1 (ko) 2023-03-17
CN107645951A (zh) 2018-01-30
CA2968926A1 (en) 2016-06-02
KR20170103776A (ko) 2017-09-13
US12318394B2 (en) 2025-06-03
US10471070B2 (en) 2019-11-12
EP3223793B1 (en) 2023-06-28
US20170266200A1 (en) 2017-09-21
US20200093834A1 (en) 2020-03-26
JP2017535592A (ja) 2017-11-30

Similar Documents

Publication Publication Date Title
CN107645951B (zh) 用于递送一种或多种生物活性剂的组合物和方法
US20220273674A1 (en) Extended-release drug delivery compositions
AU2013213514B2 (en) A drug delivery system
JP7682226B2 (ja) ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法
CN117017897A (zh) 一种埋植剂及其释药量的测试方法
EP1928424A2 (en) Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof
CN108721247B (zh) 罗哌卡因介孔生物活性玻璃复合微球制备工艺

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant